Mirae Asset Global ETFs Holdings’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-48,084
Closed -$33.8K – 3273
2026
Q1
$33.8K Buy
48,084
+1,156
+2% +$1.08K ﹤0.01% 2978
2025
Q4
$72.7K Sell
46,928
-554
-1% -$885 ﹤0.01% 2809
2025
Q3
$75K Sell
47,482
-7,857
-14% -$13.7K ﹤0.01% 2801
2025
Q2
$121K Sell
55,339
-7,242
-12% -$17.5K ﹤0.01% 2511
2025
Q1
$171K Buy
62,581
+2,652
+4% +$10.5K ﹤0.01% 2399
2024
Q4
$249K Buy
59,929
+2,584
+5% +$9.77K ﹤0.01% 2268
2024
Q3
$223K Buy
57,345
+13,416
+31% +$56.5K ﹤0.01% 2322
2024
Q2
$172K Buy
+43,929
New +$189K ﹤0.01% 2328

Other funds holding MXCT

Mirae Asset Global ETFs Holdings's MXCT Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 48,084 shares — an estimated $33.8K sold.

Mirae Asset Global ETFs Holdings first reported a position in MXCT in Q2 2024 and held it in 8 quarters. The position peaked at $249K in Q4 2024. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Mirae Asset Global ETFs Holdings reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 48,084 MaxCyte shares in Q2 2026, an estimated $33.8K.
  • Mirae Asset Global ETFs Holdings first reported a position in MaxCyte in Q2 2024 and held it in 8 quarters.
  • Mirae Asset Global ETFs Holdings's MaxCyte position peaked at $249K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.